Manual of Antibiotics and Infectious Diseases

JOHN E. CONTE, JR., M.D.

STEVEN L. BARRIERE, Pharm. D.

Fourth Edition

Manual of Antibiotics and Infectious Diseases

JOHN E. CONTE, JR., M.D.

Associate Clinical Professor of Medicine; Chief, Clinical Infectious Diseases Unit, University of California, San Francisco

STEVEN L. BARRIERE, Pharm. D.

Assistant Clinical Professor of Pharmacy; Lecturer in Pharmacology, School of Medicine, University of California, San Francisco

Fourth Edition



Lea & Febiger 600 Washington Square Philadelphia, PA 19106 U.S.A

Library of Congress Cataloging in Publication Data

Conte, John E
Manual of antibiotics and infectious diseases.

Bibliography: p.

1. Antibiotics. 2. Communicable diseases—
Chemotherapy. I. Barriere, Steven L., joint author. II. Title. [DNLM: 1. Antibiotics—
Handbooks. 2. Communicable diseases—Drug therapy—
Handbooks. QV 350 C761m]
RM267.C63 1981 616.9'0461 81-442
ISBN 0-8121-0768-3 AACR1

Copyright © 1981 by Lea & Febiger. Copyright under the International Copyright Union. All Rights Reserved. This book is protected by copyright. No part of it may be reproduced in any manner or by an means without written permission of the publisher.

Published in Great Britain by Henry Kimpton Publishers, London

PRINTED IN THE UNITED STATES OF AMERICA

Print No. 3 2 1

Preface

This manual is designed for students, housestaff, practicing physicians, and other health professionals involved in the day-to-day care of patients with infectious diseases. An attempt has been made to incorperate into 1 book a variety of important source materials that ordinarily can be found in many different locations.

The manual is divided into 9 sections:

Section I. Antibiotics

Clinically important information is presented for each antibiotic. In some instances, 2 or 3 antibiotics that are similar are discussed together. This section includes the availability and trade names of each drug, its clinical use, administration and dosage, dosage in renal insufficiency, pharmacology, adverse reactions, and drug interactions. Further reading lists are also supplied.

Section II. Pharmacokinetic Principles

Basic principles of the handling of drugs by the body are provided, with simple formulas for estimating half-life in renal insufficiency and calculating a dosage regimen for the individual patient. Recommendations are also provided for the determination of antibiotic blood levels and serum antimicrobial activity.

Section III. Empiric Antibiotic Therapy

Recommendations are made for drugs of choice, alternative therapy, appropriate dosages, and routes of administration for various clinical situations in which infection is suspected.

Section IV. Therapy of Established Infection

Empiric antibiotic therapy is continued until gram stains and cultures from the laboratory reveal 1 or more specific agents. At this point, specific therapy is begun; this section summarizes and diotic choices, doses, route of administration, and duration of therapy

Section V. Antibiotic Sensitivities

Section VI. Prophylactic Antibiotics

This section provides guidelines for the use of prophylactic antibiotics; general principles; American Heart Association recommendations for the prevention of endocarditis during various surgical procedures; American Heart Association recommendations for the prevention of rheumatic fever; tuberculosis; malaria; and meningococcal infection.

Section VII. Availability and Clinical Use of Immunobiologic Agents and Antiparasitic Drugs

These agents are available by request from the Immunobiologics, Biologic Products Division, Bureau of Laboratories, of the Center for Disease Control. Guidelines are given for the use of BCG; immune serum globulin and hepatitis B immune globulin; influenza vaccine; pneumococcal vaccine; polio vaccine; rabies immune globulin and duck embryo vaccine; zoster immune plasma; tetanus prophylaxis; immunobiologic agents and drugs distributed by the CDC and drugs for the treatment of parasitic infections.

Section VIII. Viral Hepatitis: Clinical and Serological Summary

This section includes hepatitis nomenclature; clinical comparison of Hepatitis A, B, and non-A and non-B; serologic markers and tests for hepatitis; and incidence of Hepatitis B markers in various populations.

Section IX. Syphilis and Gonorrhea

United States Public Health Service recommendations for the treatment of syphilis and gonorrhea are provided.

San Francisco, California

JOHN E. CONTE, JR. STEVEN L. BARRIERE

Abbreviations

bid	twice a day	dap
BUN	blood urea nitrogen	
CC	cubic centimeter	
CDC	Center for Disease Control	
CNS	central nervous system	
Cl _{CB}	creatinine clearance	
C _P	plasma concentration	
Crs	serum creatinine	
CSF	cerebrospinal fluid	
dl	deciliter(s)	
F.	availability (per cent oral absorption expressed as a	fraction)
FTA-ABS		
GI	fluorescent treponemal antibody absorption (test) gastrointestinal	
g.	gram(s) nonnoingly to similar	
G6PD	glucose-6-phosphate dehydrogenase (deficiency)	
hr	hour(s)	
ID	intradermal	
IM	intramuscular	
IT	intrathecal	
IU	international unit(s)	
IV	intravenous	
kd	elimination rate constant	
KF	kidney function	
kg	kilogram(s)	
L	Liter	
LD	loading dose	
LP	lumbar puncture	
M	molar	
MBC	minimum bactericidal concentration	
mcg	microgram(s)	
MD	maintenance dose	
meq	milliequivalent	
mg	milligram(s)	
MIC	minimum inhibitory concentration	
MLC	minimum lethal concentration	
ml	milliliter(s)	

purified protein derivative for rock ofin-

Sales I

xiv.	Abbreviations 200161V9	rddA
MU PO	million units by mouth	
PPD	purified protein derivative (of tuberculin)	
qd	daily, once a day	
qid qod	4 times a day every other day	
q2h	every 2 hours	
q4h	overy 4 hours	
q6h	Character Charac	BUN -
q8h	every 6 hours every 8 hours every 8 hours	riud.
q12h	every 12 hours [oning) sease(C not usens)	coc
RBC	red blood cell	UNS
RPR	rapid protein reagin	10
SIADH	syndrome of inappropriate antidiuretic hormon	e secretion
T	dosing interval	(3)
t ½	half-life built languages as	CSF
TB	tuberculosis	
tid U	s white a day and a day and a sent to some the sent to some sent to so	F
UTI	fluorescent treponemal authors, absorpania testi	FTA-ABS
V_d	volume of distribution	19.
VDR1.	Venereal Disease Research Laboratories	본
VDKL		GEPU
	hodr(s)	. H
	stradermal	O. O.
	intranti« ular	
	intrahecal	- 11
	international unit(si	
	nto avenus changation rate constant	bá
	kide v lunction	1.24-
	kalogram(s)	
	Lagrange	
	Joading dose	
	durbar practure	1.1
1	Lien	
	manhaum bactericidal concessionion	MBC
	microgram(s)	9.310
	maintenante dose	MD
	mibliequivatent	
	milligram(s)	e gm
	managan inhibitory concentration	
	minimum lethal concentration	
	milliliter(s)	

Contents

	Pemallin C	
id of	Pedicillin V (phenoxymethyl pedicillin)	
Secti	ion I. Antibiotics	
	Amantadine	2
	Amikacin	3
	Amoxicillin	4
	Amphotericin B	5.
	Ampicillin	8
	Capreomycin	9
	Carbenicillin	10
	Cefaclor	11
	Cefadroxil	12
	Cefamandole	12
	Cefazolin	13
per -	Cefoxitin	15
	Cephalexin/Cephradine	16
	Cephalothin/Cephapirin	17
	Chloramphenicol	18
	Clindamycin	20
	Cloxacillin/Dicloxacillin	21
	Colistin (Colistimethate)/Polymyxin B	22
	Cycloserine	23
	Doxycycline	24
	Erythromycin	25
	Ethambutol	26
	Ethionamide	27
	Flucytosine (5-Fluorocytosine)	28
	Gentamicin	-
9	Griseofulvin	31
	Isoniazid (INH)	32
	Kanamycin	34
	Lincomycin	35
	Methenamine	36
	Methicillin	36
	Methisazone	38
	Metronidazole	38
	Miconazole	39
	MICORACOTE	33

ix

	£	
_	Contents	~
x	Contents	1
	Minocycline	40
	Nafcillin	41
	Nalidixic Acid	42
	Nitrofurantoin	43
	Oxacillin	45
	Oxolinic Acid	46
	Para-Aminosalicylic Acid (PAS)	46
	Penicillin G	47
,	Penicillin V (phenoxymethyl penicillin) Pentamidine	50
ţ .	Pentamidine	51
4	Pyrazinamide	52
Ğ÷.	Pyrimethamine	53
4	Rifampin	54
	Spectinomycin Handsportern A.	55
8	Streptomycin	56
6	Sulfadoxine	57
10	Sulfisoxazole	58
	Tetracycline rokus 190	60
	Ticarcillin	62
12	Tobramycin	63
13	Trimethoprim and Sulfamethoxazole (Co-trimoxazole)	64
61 84	Vancomycin	66
	Validaria variatione Vigiliaria Validaria Vigiliaria Vi	67
17	Cenhalothest ephapinn (Majoramphenicol)	68
	ion II. Pharmacokinetic Principles	70
Sect	ion II. Pharmacokinetic Principles	70
	Definitions entraced (Variable Programme) (2) given (2)	71
	Achieving Therapeutic Levels of Matadaguite 1. 71 minute.	/ 1
	Minimum and Maximum Plasma Concentrations During	71
	Steady State and I was in section 2017 198 House	73
25	Dosage Adjustment for Renal Impairment	78
77	Serum Antimicrobial Activity abuntanosti 3	78
80	Floredone (25 luerosane (25 luerosane)	10
Soci	tion III. Empiric Antibiotic Therapy Pending Results of	
Seci	Appropriate Cultures	83
98	Table III-1. Empiric Antibiotic (HKI) histanos)	00
	Therapy—Cardiovascular Infection	84
	Table III-2. Empiric Antibiotic	
	Therapy—Musculoskeletal Infection	85
	Table III-3. Empiric Antibiotic Therapy—CNS Infection	86
38	Table III-4. Empiric Antibiotic Therapy—Urogenital	
38	Infection	87

Infection . . .

Table III-5. Empiric Antibiotic
Therapy—Gastrointestinal Infection

88

	Contents	xi
ari.	Table III-6. Empiric Antibiotic Therapy—Urinary	17.99
aar	Infection	89
	Table III-7. Empiric Antibiotic Therapy—Respiratory	
eal	Infection	90
160	Infection	92
Sec	tion IV. Therapy of Established Infection	93
167	Table IV-1. Infective Endocarditis	94
171	Table IV-9 Musculoskeletal Intection	97
182	Table IV-3. Pediatric Meningitis	99
		101
co. Nai	Table IV-4. Urogenital Infection	102
	Table IV-5. Acute Bacterial Gastroenteritis	104
ob i	Table IV_5A Castrointestinal Intection	106
	Table IV-7. Respiratory Infection	108
181	Table IV-8 Miscellaneous Infection	110
	Table IV-8. Miscellaneous Infections	113
Sect	ion Vital Mepatitis: Clinical and Serologic Summary V noit	120
	Table V-1. Criteria for Susceptibility to Various	
155	Table V-1. Criteria for Susceptibility to Various Antibiotics	191
	Table V–2. Minimum Inhibitory Concentrations for	
	Susceptible Organisms (mcg/ml)—Gram-Positive	
	Bacteria	122
	Table V-3. Minimum Inhibitory Concentrations for	A deg day
	Susceptible Organisms (mcg/ml)—Gram-Negative	
	Bacteria	124
	Table V-4. Minimum Inhibitory Concentrations for	141
	Susceptible Organisms (mcg/ml)—Anaerobic Bacteria	126
	Table V–5. Minimum Inhibitory Concentrations for	120
	Susceptible Organisms (mcg/ml)—Miscellaneous	
	Organisms	127
	Table V-6. Minimum Inhibitory Concentrations for	147
	Susceptible Organisms (mcg/ml)—Mycobacteria	128
		140
	Table V-7. Runyon Classification of Atypical	100
	Mycobacteria	129
Sect	ion VI. Prophylactic Antibiotics	130
	Surgical Recommendations	130
	Prevention of Bacterial Endocarditis	134
	Guidelines for Isoniazid Prophylaxis of Tuberculous	
	Infection	140
	Prevention of Rheumatic Fever	143
	Guidelines for Meningococcal Prophylaxis	150
	Malaria Chemoprophylavis	159

	Contents
XII	

Section VII. Availability and Clinical Use of Immunobiologic	
Agents and Antiparasitic Drugs	156
BCG Vaccine	156
Botulism Equine Antitoxin (ABE)	158
Diphtheria Equine Antitoxin	159
Immune Serum Globulin and Henatitis B Immune Globulin	160
Influenza Vaccine	161
Influenza Vaccine Pneumococcal Vaccine Poliomyelitis Vaccines	165
Poliomyelitis Vaccines	167
Rables Trevelluoli	171
Tetanus Prophylaxis in Wound Management	182
vaccinia Immune Globulin (VIG)	183
Varicella Zoster Immune Globulin (Human VZIG)	184
Zoster Immune Plasma	186
Immunobiologic Agents and Drugs Distributed by the	
Center for Disease Control	187
Clinical Use of Antiparasitic Drugs	192
Section VIII. Viral Hepatitis: Clinical and Serologic Summary	217
Section VIII. Viral Hepatitis: Clinical and Serologic Summary Section IX. Syphilis and Gonorrhea	224
Angeones Lable V 2. Minimum Inhibitory Concentrations for	
Susceptible Organisms (mcg/ml)—Crime-Positive	
eot	
Lable V-3. Meningun ledabitory (Socientiquens (or	
Susceptible Organisms on gind —Gram "regative	
Radiana Caramana magamana Pantana 121	
Lable, V-1. Minimary Inhilino - Concernations for	
Susceptible organisms (og gomb) - Anaerolae Baro rin 120	
Susceptible Organizers (meg/mt)Miscellance us	
Lable V-7. Runyon Christicanon of Asspical	
Nycoban eria	
Infection 140	

and Prodominar acturous Penicilin der 2017 OISTNA illin. relataging hald manife for the treatning of scrious orangesative crimethoprim as a sole agent, which may be useful in chose comments

The summaries of antibiotics that follow are designed to provide the clinician with an overview of the clinical use of each agent, along with pertinent facts concerning comparative efficacy and toxicity, if similar agents are available. Each section provides information on appropriate dosage and administration in patients with normal and impaired renal function and other important clinical pharmacologic parameters. Sections on adverse reactions and significant drug interactions are provided, and finally, a few references are listed to allow the reader to review each agent in more depth or to investigate more controversial ineffective against influence B. Glinical use of amantachae is susanion

An attempt is made to provide information on all currently useful antibiotics. Older drugs that have fallen into relative disuse are not included. For example, semisynthetic penicillins such as phenethicillin or hetacillin, cephalosporins such as cephaloridine or cephaloglycin, aminoglycosides such as neomycin, or agents such as triacetyloleandomycin have little to no role in current clinical medicine and are either less effective or more toxic than new agents. Recent clinical data suggest that tobramycin is the least nephrotoxic aminoglycoside currently available, and the recommendations contained in the manual reflect this finding. Our experience and other clinical data document the relative lack of interstitial nephritis secondary to nafcillin. Since methicillin is associated with a significant incidence of nephritis, and since oxacillin is hepatotoxic, recommendations in the manual are for the use of nafcillin in the treatment of staphylococcal infection.

Several tetracycline and sulfonamide derivatives are deliberately excluded, since these analogs offer no advantage over tetracycline or sulfisoxazole in the treatment of infectious diseases. Exceptions to this are noted in the summaries of each drug. It must be emphasized that although the summaries reflect the majority of opinions on clinical use, they also contain our opinions and interpretation of the available data, as well as our experiences.

At the time of this writing, several semisynthetic penicillins and cephalosporins are being tested in clinical trials. A few of these agents may shortly become commercially available. They all possess enhanced activity against many gram-negative bacilli, notably Serratia marcescens and Pseudomonas aeruginosa. Penicillin derivatives such as piperacillin. azlocillin, and mezlocillin and cephalosporins such as cefoperazone and cefotaxime hold promise for the treatment of serious gram-negative bacillary infection, without the potential for nephro- or ototoxicity.

Other agents that will soon be available and may be useful in selected situations include: cefuroxime, a cephalosporin active against the gonococcus, including penicillinase-producing strains (PPNG): trimethoprim as a sole agent, which may be useful in those patients with recurrent UTI who cannot tolerate a sulfonamide; and netilmicin. an aminoglycoside, active against many gentamicin- or tobramycinresistant gram-negative bacilli, that may be less toxic than gentamicin.

AMANTADINE

This drug is available as a red capsule containing 100 mg and as a

syrup containing 10 mg/ml.

Clinical Use. Amantadine, a synthetic antiviral agent, inhibits RNA viral replication and prevents the penetration of virus into susceptible cells. It is only active against strains of influenza A virus. The drug is ineffective against influenza B. Clinical use of amantadine is suggested in the following:

a. household contacts

b. prevention of institutional spread prophylaxis

c. unvaccinated adults at high risk that Jarogzolasigos millosted to

d. treatment of acute infection within 48 hours of onset of illness, in an attempt to lessen symptomatology

Administration and Dosage. Adults and older children: 100 mg (1 capsule or 10 ml of syrup) PO bid, for treatment or prophylaxis. Younger children (<10 years old): 3 mg/kg/day. Since the drug is effective for prophylaxis during the period of administration only, it should be given for 10 days after exposure to a single case and up to as long as 4 to 6 weeks with repeated exposure during an epidemic.

Dosage in Renal Insufficiency. The drug is nearly entirely excreted unchanged, so dosage should be reduced in proportion to the decrease in creatinine clearance. Hemodialysis has little effect on clearance.

No data are available regarding peritoneal dialysis.

Pharmacology. Serum concentrations have not been correlated with therapeutic effect. The serum half-life is approximately 12 hours in patients with normal renal function. Excretion is enhanced by acidification of the urine.

Adverse Reactions

CNS Toxicity. Nervousness, dizziness, agitation or ataxia, drowsiness, and insomnia may result.

Anticholinergic Reactions. Blurred vision, dry mouth, and tachycardia may occur.

Gastrointestinal Disturbance. Anorexia and nausea are mild.

Teratogenic Reactions. None are reported.

Drug Interactions. None are known.

Further Reading and advantage and area

Monto, A.S., et al.: Prevention of Russian influenza by amantadine. J.A.M.A., 241:1003, 1979.

AMIKACIN 1

This drug is available as solution for injection in vials containing 500 mg/2 ml, 1000 mg/4 ml, and 100 mg/2 ml for pediatric use. (Amikin)

Clinical Use. Amikacin is a semisynthetic amihoglycoside active against nearly all gram-negative bacilli, including many strains resistant to gentamicin or tobramycin. Amikacin is bactericidal and inhibits protein synthesis by binding to the 30s subunit of bacterial ribosomes. Many institutions, including our own, have restricted its use to infections caused by resistant organisms. The effects of this restricted use on the emergence of resistance to amikacin is unknown. It is clinically useful in a variety of infections due to susceptible pathogens, including infections of bones and joints, the respiratory tract, soft tissue and wounds, the urinary tract, and the central nervous system, as well as septicemia.

Administration and Dosage. Adults and children: 15 to 20 mg/kg/day IM/IV, in 2 or 3 divided doses. Neonates and infants: maximum of 15 mg/kg/day IM/IV. Older children may receive 20 to 30 mg/kg/day IM/IV. The dose is diluted into 100 to 200 ml of a compatible IV solution and is infused over 30 to 60 minutes. Intrathecal or intraventricular dosage for meningitis is 10 to 15 mg per day.

Dosage in Renal Insufficiency. One should consult the nomogram (see Table II-2) for adjusting aminoglycoside dosage or refer to the section on pharmacokinetic principles to estimate half-life. A loading dose should always be administered to achieve adequate serum levels. Subsequent doses may then be reduced, based on the patient's renal function. The half-life of amikacin during hemodialysis is approximately 4 hours. Peritoneal dialysis has little effect on the drug's half-life.

Pharmacology

lynseint fections, tage, of	Dosage mg/kg IV	Serum Concen- tration (mcg/ml)	Urinary Concen- tration (mcg/ml)	V _D	Normal t½ (hr)	Anuria t½ (hr)	Protein Bound (%)	Excreted Unchanged (%)
Adult	7.5	20-30	500-1000	0.25-0.3	2	≥48	Low	90-95
Neonate	7.5	15-20	500-1000	0.5-0.6	5-7	≥48	Low	90-95
Child	7.5	20-25	500-1000	0.3	1.5	≥48	Low	90-95

CSF penetration; variable; maximum of 40 to 50% of serum levels. but IT administration is required. Pleural and ascitic fluid levels are nearly equal to serum levels one appropriate landstanding levels of the levels of the

Adverse Reactions

Ototoxicity. High-frequency hearing loss and tinnitus occur after prolonged (>10 to 14 days) therapy. Hearing loss in the conversational range and vestibular damage are rare, but may be irreversible.

Nephrotoxicity. Acute tubular necrosis occurs in 5 to 10% of patients and is manifested by increases in serum creatinine and BUN.

Neuromuscular Blockade. This has only been reported with kanamycin. or neomycin, administered by intraperitoneal lavage, and in patients given full IV dosage in the presence of renal insufficiency. Drug Interactions ni noitteini nel nonulos as eldelises at ment sid F

Cephalosporins. The potential for synergistic nephrotoxicity exists. although this is controversial and has only been documented for gentamicin and tobramycin.

Potent Diuretics (furosemide, ethacrynic acid). These are felt to potentiate

oto- or nephrotoxicity presumably due to volume contraction.

Penicillins. Inactivation of the aminoglycosides is caused in vitro and in vivo, Caution should be exercised in patients with renal insufficiency, in whom excessive concentrations of penicillins may result in decreased aminoglycoside concentrations. Amikacin is inactivated to a lesser extent than the other agents. The clinical significance of this interaction wounds, the urinary tract, and the central nervous system (working at

Miscellaneous. Aminoglycosides may enhance the nephrotoxicity of platinum compounds, amphotericin B, and polymyxins. day IM/IV, in 2 or 3 divided doses. Neopaies and infants: maximum of

15 mg/kg/day LM/IV. Older children may receive 20 tr gnibas ruther

Finland, M., et al.: Advances in aminoglycoside therapy—amikacin. J. Infect. Dis. [Suppl.], 134:51, 1976.

Hewitt, W.L., et al.: U.S. amikacin symposium. Am. J. Med., 62:1, 1977. Bosage in Repai lasufficiency. One should consult the nomogram

sertion on pharmacokinetic NIJIDIXOMAStimate half-life. A loading

This drug is available in capsules containing 250 mg and 500 mg and in oral suspensions containing 125 mg/5 ml and 250 mg/5 ml. (Larotid, Amoxil, and others)

Clinical Use. Amoxicillin is a semisynthetic analog of ampicillin. Except for shigella, its in vitro activity is similar to that of ampicillin (see ampicillin for spectrum and mechanism of action). It is clinically useful in urinary tract infections, upper and lower respiratory tract infections, skin and soft-tissue infections, and gonorrhea. An advantage of amoxicillin over oral ampicillin is more reliable absorption, resulting in serum levels that are approximately twice as high. Amoxicillin may be

Antibiotics and Infectious Diseases useful in the chronic treatment of endocarditis or osteomyelitis, if compliance and adequate serum bactericidal activity can be assured.

Administration and Dosage. Adults and children: 25 to 100 mg/kg/ day in 3 or 4 divided doses depending on the severity and the site of

Dosage in Renal Insufficiency. See ampicillin.

Pharmacology

	Dosage	Concen- tration		V _D L/kg	Normal t½ (hr)	Anuria t½ (hr)	Bound	Excreted Unchanged (%)
Adult	500	7-8	500-2500	0.4	1	16	Low	40–70

CSF penetration; concentrations of 5 to 10% of serum levels in the presence of inflamed meninges. That is it slightlesses north attend & co the daily dose by 5-mg increments to a tolerable leaning of the daily dose by

Hypersensitivity Reactions. As with all penicillins, rash, urticaria, anaphylaxis, and serum sickness are possible, but are uncommon.

Gastrointestinal Disturbance. In children, amoxicillin may produce less diarrhea than ampicillin when given in oral suspensions.

Drug Interactions. See penicillin G. 2011 1639 144 161 2019 1639 163 choose solution, via the himbar rouse, water immediate to

Further Reading courrying eroyal anothers a guidendelement out mentag

Neu, H.C.: Amoxicillin, Ann. Intern. Med., 90:356, 1979.

AMPHOTERICIN B (AmB) of erragge biotises

This drug is available in vials containing 50 mg for reconstitution for intravenous use or irrigations and in lotion, cream, and ointment, in 3% concentration. (Fungizone)

Clinical Use. The topical formulations of amphotericin B are useful for the treatment of cutaneous or mucocutaneous candidiasis. The parenteral product is useful in the treatment of cryptococcosis, North American blastomycosis, disseminated candidiasis, coccidioidomycosis, histoplasmosis, mucormycosis, sporotrichosis, and aspergillosis. The drug is generally fungistatic, but may be fungicidal. It binds to sterols in the fungal cell wall and produces leakage of cellular contents. Irrigations of the urinary bladder may be performed in the treatment of candidal cystitis. Peritoneal lavage and intra-articular irrigation with amphotericin B may be useful in peritonitis and in septic arthritis.

Administration and Dosage. There is no universal agreement on the method of adminstration, the rate of infusion, or the daily or total dose of AmB. Further, the effect of the foregoing on systemic toxicity and nephrotoxicity has not been studied and is controversial. We recommend the following procedure:

Critically III Patients	Alternate Procedure			
Test Dose (1 mg) Day 1	Test Dose (1 mg) Day 1			
0.25 mg/kg Day 1	5 mg Day 1			
0.5 mg/kg Day 2	10 mg Day 2			
0.75 mg/kg Day 3	15 mg Day 3			
Increase dose or maintain, as toler-	20 mg Day 4			
ated by patient	25 mg Day 5			
	30 mg Day 6			
Esteroid esteril shund lamini	Increase dose by 5-mg increments or maintain, as tolerated by patient			

If Cr_S reaches 2.5 to 3.0 mg/dL, one should discontinue AmB for 24 to 48 hours, then reinstitute it at half the previous dose, and increase the daily dose by 5-mg increments to a tolerable level. The desired dose should be diluted in 250 to 500 ml of 5% dextrose in water and administered over 4 to 6 hours. Solutions do not need protection from light. Intrathecal administration is important in the treatment of coccidioidal meningitis and occasionally may be necessary in cryptococcal meningitis. Intrathecal injection: administration of AmB in 10% glucose solution, via the lumbar route, with immediate lowering of the patient into Trendelenburg's position, favors migration of drug to the occipital region. This procedure obviates the need for repeated cisternal punctures or for prolonged ventricular reservoir placement. This method appears to be efficacious, since the most severe coccidioidal lesions are at the base of the brain.

One should add 0.25 to 0.5 mg of AmB to 5 ml of 10% dextrose with 25 mg hydrocortisone, inject hydrocortisone 25 mg into LP site, and then inject hyperbaric AmB solution. The patient should be lowered immediately into Trendelenburg's position for 45 minutes.

For bladder irrigation, 25 to 50 mg of the drug should be added to 500 to 1000 ml of sterile water. One should never add amphatericin B to saline-containing solutions.

Dosage in Renal Insufficiency. Serum levels are not altered by impaired renal function. If the renal failure is felt to be due to the drug, then the following is recommended: When serum creatinine reaches 2.5 to 3.0 mg/dL, one should discontinue the drug for 24 to 48 hours, as the patient's condition allows, and reinstitute therapy at approximately half the previous dosage. Then daily dosage should be increased by 5-mg increments until the desired level is reached. This approach may ameliorate further decline in renal function. Alternatively, although this is unproven, administering the drug every other day, as soon as possible, may help to prevent nephrotoxicity.

Hemo- and peritoneal dialysis do not affect the clearance of AmB.